PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

There is a lack of strategies for patients who progress after responding to PD-1/l-1 in melanoma. High expression of Nectin4 in skin and melanomas may serve as a new target in advanced melanomas. The combination of enfortumab/vedotin (EV) and pembrolizumab has shown synergistic effect in various solid tumors. Enfortumab vedotin and pembrolizumab may have a dual effect on clinical outcomes. PLUGIN is a multicenter, non-randomized open-label, 2-cohort, phase 2 study to evaluate the ORR of pembrolizumab in combination with enfortumab vedotin (EV) in previously treated participants with unresecta

Trial Details

NCT ID
NCT06906822
Phase
PHASE2
Sponsor
Grupo Español Multidisciplinar de Melanoma
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • enfortumab vedotin
  • pembrolizumab
Locations (sample)
  • A Coruña, A Coruña, Spain|43.37135,-8.396
  • Badalona, Barcelona, Spain|41.45004,2.24741
  • Barcelona, Barcelona, Spain|41.38879,2.15899
  • Barcelona, Barcelona, Spain|41.38879,2.15899
  • Barcelona, Barcelona, Spain|41.38879,2.15899

Key Eligibility Criteria

  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of unresec…
  • Participants must have measurable disease by investigator assessment according to RECIST v1.1 Participants with prior definitive radiation therapy …
  • Male participants:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →